Once-Daily gabapentin 300 MG Oral Tablet — RxCUI 1806380
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Gabapentin: what it is, how it’s used, side effects, and interactions.
- It manages nerve pain after shingles (postherpetic neuralgia). Many gabapentin products are also add-on treatment for partial seizures in epilepsy. Horizant is also used for restle...
- Be careful. Gabapentin can make you sleepy and dizzy and may impair driving. Don't drive or use heavy machinery until you know how it affects you, since it can be hard to judge you...
- Don't stop it on your own. For seizures, stopping suddenly can increase seizure frequency. Reports also describe withdrawal symptoms such as anxiety, trouble sleeping, nausea and s...
- Missed-dose advice depends on the product. With Horizant, for restless legs syndrome take the next dose the following day, and for postherpetic neuralgia skip it and take the next...
🕸️ Concept Web — How Once-Daily gabapentin 300 MG Oral Tablet Connects
RxCUI 1806380 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Gabapentin
25480IN
-
Gabapentin
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Gralise
1087976BN
-
Gralise
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Gabapentin Oral Tablet
378099SCDF -
Gabapentin Oral Product
1156681SCDG -
Gabapentin Pill
1156682SCDG -
Gabapentin Oral Tablet [Gralise]
1115011SBDF -
Gralise Oral Product
1172653SBDG -
Gralise Pill
1172654SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Gabapentin Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Gabapentin 300 MG
345818SCDC -
Once-Daily gabapentin 300 MG Oral Tablet [Gralise]
1115012SBD -
Gabapentin 300 MG [Gralise]
1087977SBDC
-
Gabapentin 300 MG
-
Packs 2
Fixed collections of drugs packaged and sold together, like dose packs.
🔀 Generic ⇄ Brand Crosswalk
Generic (Clinical) Concepts
-
{9 (Once-Daily gabapentin 300 MG Oral Tablet) / 24 (Once-Daily gabapentin 600 MG Oral Tablet) } Pack
GPCK · 2398511 -
Gabapentin 300 MG
SCDC · 345818 -
Gabapentin Oral Tablet
SCDF · 378099 -
Gabapentin Oral Product
SCDG · 1156681 -
Gabapentin Pill
SCDG · 1156682
Brand-Name Concepts
-
Once-Daily gabapentin 300 MG Oral Tablet [Gralise]
SBD · 1115012 -
{9 (Once-Daily gabapentin 300 MG Oral Tablet [Gralise]) / 24 (Once-Daily gabapentin 600 MG Oral Tablet [Gralise]) } Pack [Gralise Sample Pack]
BPCK · 2398512 -
Gabapentin 300 MG [Gralise]
SBDC · 1087977 -
Gabapentin Oral Tablet [Gralise]
SBDF · 1115011 -
Gralise Oral Product
SBDG · 1172653 -
Gralise Pill
SBDG · 1172654 -
Gralise
BN · 1087976
📦 FDA Products & Package NDCs
21 products · 39 package NDCs
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 31722-0091-90 | 90 TABLET, FILM COATED in 1 BOTTLE (31722-091-90) | GABAPENTIN | Camber Pharmaceuticals, Inc. | 2024-02-26 |
| 31722-0092-90 | 90 TABLET, FILM COATED in 1 BOTTLE (31722-092-90) | GABAPENTIN | Camber Pharmaceuticals, Inc. | 2024-02-26 |
| 42806-0656-09 | 90 TABLET in 1 BOTTLE (42806-656-09) | Gabapentin | Epic Pharma, LLC | 2024-02-26 |
| 42806-0657-09 | 90 TABLET in 1 BOTTLE (42806-657-09) | Gabapentin | Epic Pharma, LLC | 2024-02-26 |
| 50228-0523-05 | 500 TABLET in 1 BOTTLE (50228-523-05) | gabapentin | ScieGen Pharmaceuticals, Inc. | 2025-09-20 |
| 50228-0523-30 | 30 TABLET in 1 BOTTLE (50228-523-30) | gabapentin | ScieGen Pharmaceuticals, Inc. | 2025-09-20 |
| 50228-0523-90 | 90 TABLET in 1 BOTTLE (50228-523-90) | gabapentin | ScieGen Pharmaceuticals, Inc. | 2025-09-20 |
| 50228-0524-05 | 500 TABLET in 1 BOTTLE (50228-524-05) | gabapentin | ScieGen Pharmaceuticals, Inc. | 2025-09-20 |
| 50228-0524-30 | 30 TABLET in 1 BOTTLE (50228-524-30) | gabapentin | ScieGen Pharmaceuticals, Inc. | 2025-09-20 |
| 50228-0524-90 | 90 TABLET in 1 BOTTLE (50228-524-90) | gabapentin | ScieGen Pharmaceuticals, Inc. | 2025-09-20 |
| 52427-0803-90 | 90 TABLET, FILM COATED in 1 BOTTLE (52427-803-90) | Gralise | Almatica Pharma LLC | 2020-10-01 |
| 52427-0804-60 | 60 TABLET, FILM COATED in 1 BOTTLE (52427-804-60) | Gralise | Almatica Pharma LLC | 2023-12-31 |
| 52427-0806-90 | 90 TABLET, FILM COATED in 1 BOTTLE (52427-806-90) | Gralise | Almatica Pharma LLC | 2020-10-01 |
| 52427-0850-60 | 60 TABLET, FILM COATED in 1 BOTTLE (52427-850-60) | Gralise | Almatica Pharma LLC | 2023-12-31 |
| 52427-0890-60 | 60 TABLET, FILM COATED in 1 BOTTLE (52427-890-60) | Gralise | Almatica Pharma LLC | 2023-12-31 |
| 68382-0355-01 | 100 TABLET in 1 BOTTLE (68382-355-01) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0355-14 | 60 TABLET in 1 BOTTLE (68382-355-14) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0356-01 | 100 TABLET in 1 BOTTLE (68382-356-01) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0356-14 | 60 TABLET in 1 BOTTLE (68382-356-14) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0357-01 | 100 TABLET in 1 BOTTLE (68382-357-01) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0357-14 | 60 TABLET in 1 BOTTLE (68382-357-14) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0607-05 | 500 TABLET in 1 BOTTLE (68382-607-05) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0607-16 | 90 TABLET in 1 BOTTLE (68382-607-16) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0607-77 | 10 BLISTER PACK in 1 CARTON (68382-607-77) / 10 TABLET in 1... | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0608-05 | 500 TABLET in 1 BOTTLE (68382-608-05) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0608-16 | 90 TABLET in 1 BOTTLE (68382-608-16) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0608-77 | 10 BLISTER PACK in 1 CARTON (68382-608-77) / 10 TABLET in 1... | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 70771-1861-02 | 10 TABLET in 1 BLISTER PACK (70771-1861-2) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1861-05 | 500 TABLET in 1 BOTTLE (70771-1861-5) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1861-09 | 90 TABLET in 1 BOTTLE (70771-1861-9) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1862-04 | 10 BLISTER PACK in 1 CARTON (70771-1862-4) / 10 TABLET in 1... | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1862-05 | 500 TABLET in 1 BOTTLE (70771-1862-5) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1862-09 | 90 TABLET in 1 BOTTLE (70771-1862-9) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1916-01 | 100 TABLET in 1 BOTTLE (70771-1916-1) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1916-06 | 60 TABLET in 1 BOTTLE (70771-1916-6) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1917-01 | 100 TABLET in 1 BOTTLE (70771-1917-1) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1917-06 | 60 TABLET in 1 BOTTLE (70771-1917-6) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1918-01 | 100 TABLET in 1 BOTTLE (70771-1918-1) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1918-06 | 60 TABLET in 1 BOTTLE (70771-1918-6) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
🗃️ Sources & Limits
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.